![Philippe Lievre](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Oorsprong van het eerstegraads netwerk van Philippe Lievre
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Priothera Ltd.
![]() Priothera Ltd. BiotechnologyHealth Technology Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland.
8
| Holding Company | Biotechnology | 8 |
Priothera SAS
![]() Priothera SAS BiotechnologyHealth Technology Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020.
4
| Subsidiary | Biotechnology | 4 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Philippe Lievre via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
AMARIN CORPORATION PLC | Pharmaceuticals: Major | Director/Board Member | |
Novartis International AG
![]() Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Fountain Healthcare Partners Ltd.
![]() Fountain Healthcare Partners Ltd. Investment ManagersFinance Fountain Healthcare Partners Ltd. (Fountain) is venture capital firm, founded in 2008 by Manus Rogan and Aidan King. The firm is headquartered in Dublin, Ireland. | Investment Managers | Founder | |
RA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
ULTRAGENYX PHARMACEUTICAL INC. | Pharmaceuticals: Major | Director/Board Member | |
MAINSTAY MEDICAL INTERNATIONAL | Medical Specialties | Director/Board Member | |
HealthCap AB
![]() HealthCap AB Investment ManagersFinance HealthCap AB (HealthCap) is a venture capital subsidiary of Odlander, Fredrikson & Co. AB founded in 1995 by Björn Ingemar Odlander and Peder Fredrikson. The firm is headquartered in Stockholm, Sweden with an additional office in Switzerland. | Investment Managers | Private Equity Investor | |
GSK PLC | Pharmaceuticals: Major | Corporate Officer/Principal | |
Duke University
![]() Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | College/University | Doctorate Degree | |
UCB | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
The University of North Carolina at Chapel Hill | College/University | Corporate Officer/Principal | |
Trinity College Dublin | College/University | Masters Business Admin | |
Novartis Venture Funds
![]() Novartis Venture Funds Investment ManagersFinance Novartis Venture Funds (NVF) is a venture capital firm with headquarters in Basel, Switzerland and an additional office in Cambridge, MA. The firm was founded in 1996. NVF is a subsidiary of Novartis AG (VX: NOVN) and was created following the 1996 merger of Ciba-Geigy and Sandoz. | Investment Managers | Private Equity Investor Chief Investment Officer | |
SelectX Pharmaceuticals, Inc.
![]() SelectX Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SelectX Pharmaceuticals, Inc. engages in the discovery and development of aminoglycoside therapeutics for unmet medical needs. Its advanced program, development candidate SXP2523, is a next generation aminoglycoside antibiotic for drug resistant gram-negative hospital-acquired infections (HAIs); SXP2523 possesses broad spectrum coverage with potency against Pseudomonas, Klebsiella, Acinetobacter, E. coli, and Staphylococcus. The company was founded by Michael G. Chaparian and Charles R. Cantor in 2002 and is headquartered in Boston, MA. | Pharmaceuticals: Major | Chief Executive Officer | |
The University of York | College/University | Doctorate Degree | |
University of Lund | College/University | Doctorate Degree | |
Ruprecht-Karls-Universität Heidelberg | College/University | Doctorate Degree | |
Novartis Institutes for Biomedical Research, Inc.
![]() Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA. | Miscellaneous Commercial Services | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Duke University Medical Center | College/University | Corporate Officer/Principal | |
Altimmune UK Ltd.
![]() Altimmune UK Ltd. BiotechnologyHealth Technology Altimmune UK Ltd. engages in the discovery and development of prophylactic and therapeutic vaccines against mutating viruses and cancer. It provides T-cell vaccines to protect patients against infectious diseases (most notably mutating viruses) and to treat cancers; and Flunisyn, a DepoVaccine to protect against influenza. The company was founded by Bertrand Georges in 2003 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member | |
MERUS N.V. | Biotechnology | Director/Board Member Director/Board Member | |
binx health, inc.
![]() binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | Information Technology Services | Director/Board Member | |
FerroKin BioSciences, Inc.
![]() FerroKin BioSciences, Inc. Pharmaceuticals: MajorHealth Technology FerroKin BioSciences, Inc. offers clinical stage biotechnology services for iron chelator in the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemia. The company was founded by Hugh Young Rienhoff, Jr. in 2007 and is headquartered in San Carlos, CA. | Pharmaceuticals: Major | Director/Board Member | |
MyoPowers Medical Technologies France SAS
![]() MyoPowers Medical Technologies France SAS Medical SpecialtiesHealth Technology MyoPowers Medical Technologies France SA operates as a medical device company. It specializes in muscle technologies to restore or improve muscle function. The firm also develops implantable medical devices for the treatment of severe stress urinary incontinence. The company was founded by Piergiorgio Tozzi and Daniel Hyoz in June 2004 and is headquartered in Lausanne, Switzerland. | Medical Specialties | Director/Board Member Director of Finance/CFO | |
Opsona Therapeutics Ltd.
![]() Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member Chairman | |
POWERLAND AG | Consumer Sundries | Director/Board Member | |
Irish Venture Capital Association
![]() Irish Venture Capital Association Investment ManagersFinance The Irish Venture Capital Association is a representative organization for venture capital and private equity firms in Ireland. The Irish company invests in private, unlisted companies with high growth potential and work with the investee company management teams to support growth plans and make improvements to the business with the aim of increasing its value. The IVCA offers a range of services to its members and benefits of membership. The company's full members are venture capital and private equity firms that provide equity funding to growing unquoted companies. Associate members of the IVCA include firms that provide advisory services including corporate finance houses, commercial and intellectual property law firms, accountants and other advisers experienced in the venture capital field. | Investment Managers | Chairman | |
Mainstay Medical Ltd.
![]() Mainstay Medical Ltd. Medical SpecialtiesHealth Technology Mainstay Medical Ltd. operates as a medical device company which develops neuro-stimulation therapies for people with debilitating chronic low back pain. It develops ReActiv8, an active implantable medical device designed to treat people with chronic low back pain. The company was founded by Danny Sachs in 2008 and is headquartered in Dublin, Ireland. | Medical Specialties | Director/Board Member | |
GENSIGHT BIOLOGICS S.A. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
WILSON THERAPEUTICS AB | Pharmaceuticals: Major | Director/Board Member | |
Anokion SA
![]() Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
Opsona Research Ltd.
![]() Opsona Research Ltd. MiscellaneousMiscellaneous Opsona Research Ltd. is a private company headquartered in Dublin, Ireland. The firm functions as an investment holding company. | Miscellaneous | Director/Board Member | |
Kanyos Bio, Inc.
![]() Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Neuromod Devices Ltd.
![]() Neuromod Devices Ltd. Medical SpecialtiesHealth Technology Neuromod Devices Ltd. operates as a medical device company which engages in the research and development of neuromodulation technologies for chronic tinnitus. The firm develops proprietary neuromodulation technologies designed to address pathologies, which are believed to give rise to illusory perceptions, such as tinnitus. These technologies utilize bi-modal neuromodulation and aim to promote positive therapeutic change within the human nervous system. The company was founded by Ross O?Neill in 2010 and is headquartered in Dublin, Ireland. | Medical Specialties | Chairman | |
Oculis SA
![]() Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member Chairman | |
Inflazome Ltd.
![]() Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
Imcheck Therapeutics SAS
![]() Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Pharmaceuticals: Major | Director/Board Member | |
Investinswitzerland | Founder | ||
Grayling Schweiz AG | Chief Executive Officer | ||
Vivet Therapeutics SAS
![]() Vivet Therapeutics SAS BiotechnologyHealth Technology Vivet Therapeutics SAS develops novel gene therapy treatments for inherited metabolic diseases. The firm offers its services under the categorizers of Biopharma, Biotechnology and Health Care. The company was founded by Jean-Philippe Combal, Gloria Gonzalez-Aseguinolaza and Jens Kurth on July 26, 2016 and is headquartered in Paris, France. | Biotechnology | Chairman Director/Board Member | |
IQVIA | Corporate Officer/Principal | ||
Quell Therapeutics Ltd.
![]() Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
CAPTOR THERAPEUTICS SPOLKA AKCYJNA | Pharmaceuticals: Major | Director/Board Member | |
Swissvention Partners GmbH | Chief Executive Officer | ||
Amyl Therapeutics SRL
![]() Amyl Therapeutics SRL BiotechnologyHealth Technology Amyl Therapeutics SRL is a Belgian biotech company that uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-? (A?), tau, and ?-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. Amyl Therapeutics is based in Liege, BE and was founded in November 2020 by Drs. The company's therapies based on the clarity technology platform are designed to prevent the further accumulation of aggregates and clear existing aggregates from the peripheral organs and the brain, while also blocking further cell-to-cell spread of misfolded proteins. Florent Gros and Pierre Vandepapelière. Pierre Vandepapelière has been the CEO since incorporation. | Biotechnology | Founder |
Statistieken
Internationaal
Verenigde Staten | 14 |
Ierland | 10 |
Zwitserland | 8 |
Verenigd Koninkrijk | 6 |
Frankrijk | 5 |
Sectoraal
Health Technology | 27 |
Consumer Services | 8 |
Finance | 5 |
Commercial Services | 3 |
Health Services | 3 |
Operationeel
Director/Board Member | 87 |
Corporate Officer/Principal | 24 |
Independent Dir/Board Member | 12 |
Founder | 12 |
Chairman | 10 |
Sterkste connecties
Insiders | |
---|---|
Henry Skinner | 29 |
Florent Gros | 28 |
Lionel Carnot | 27 |
Marten Steen | 21 |
Manus Rogan | 15 |
Dhavalkumar Patel | 12 |
Brice R. Suire | 9 |
Stephan Oehen | 6 |
Simone Seiter | 6 |
- Beurs
- Insiders
- Philippe Lievre
- Bedrijfsconnecties